Discover more from Courageous Discourse™ with Dr. Peter McCullough & John Leake
NEURO-COVAX: Italian Network Finds Neurological Side Effects Very Common after COVID-19 Vaccination
31.2% Experienced Tremors, Insomnia, Muscle Spasms, Headaches, Paresthesias, Vertigo, and Diplopia
By Peter A. McCullough, MD, MPH
I have been struck by the wide range of neurological syndromes I see in the office in patients who took one or more of the ill-advised COVID-19 vaccines. Many times I wonder what the risk is from population studies? Is my practice similar to what is seen in the medical literature?
Salsone et al, reported from Milan, Italy, results from the NEURO-COVAX Study. As a general reference, when there is a 20% or more excess risk, that is an odd’s ratio, relative risk, or hazard ratio of 1.20 or greater, it is clinically important.
The NEURO-COVAX-cohort included 19,108 vaccinated people: 15,368 with BNT162b2 (Pfizer), 2,077 with mRNA-1273, 1,651 with ChAdOx1nCov-19, and 12 with Ad26.COV2.S who were subsequently excluded. Approximately 31.2% of the sample developed post-vaccination neurological complications, particularly with ChAdOx1nCov-19. A vulnerable clinical profile emerged, where over 40% of the symptomatic people showed comorbidities in their clinical histories. Defining the neurological risk profile, we found an increased risk for ChAdOx1nCov-19 of tremors (vs. BNT162b2, OR: 5.12, 95% CI: 3.51-7.48); insomnia (vs. mRNA-1273, OR: 1.87, 95% CI: 1.02-3.39); muscle spasms (vs. BNT162b2, OR: 1.62, 95% CI: 1.08-2.46); and headaches (vs. BNT162b2, OR: 1.49, 95% CI: 0.96-1.57). For mRNA-1273, there were increased risks of paresthesia (numbness and tingling) (vs. ChAdOx1nCov-19, OR: 2.37, 95% CI: 1.48-3.79); vertigo (vs. ChAdOx1nCov-19, OR: 1.68, 95% CI: 1.20-2.35); diplopia (double vision) (vs. ChAdOx1nCov-19, OR: 1.55, 95% CI: 0.67-3.57); and sleepiness (vs. ChAdOx1nCov-19, OR: 1.28, 95% CI: 0.98-1.67). In the period that ranged from March to August 2021, no one was hospitalized and/or died of severe complications related to the primary series of two COVID-19 vaccines. Hospitalization or death after one shot was not captured.
In summary, a shocking 31.2% of respondents to this large dataset sustained neurologic injury after two injections with verified data in health registries. Most of the risk estimates indicate the safety profile is unacceptable. It is alarming that all neurological societies to date still recommend COVID-19 vaccines and none have issued safety warnings on the products.
In my practice, I have found 3-12 months of McCullough Protocol Base Spike Detoxification (BSD) in addition to other drugs is a reasonable approach to these problems once serious intracranial pathology has been excluded. The fundamental principle of degradation of the Spike protein appears to be pivotal to managing these clinical syndromes. In my experience, additional agents including corticosteroids, gabapentin, NAC, nicotine, and low-dose naltrexone can help with symptoms, but without BSD, cannot resolve the problem.
Please subscribe to Courageous Discourse as a paying or founder member so we can continue to bring you the truth.
Courageous Discourse™ with Dr. Peter McCullough & John Leake is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.
Peter A. McCullough, MD, MPH
President, McCullough Foundation
Salsone M, Signorelli C, Oldani A, Alberti VF, Castronovo V, Mazzitelli S, Minerva M, Ferini-Strambi L. NEURO-COVAX: An Italian Population-Based Study of Neurological Complications after COVID-19 Vaccinations. Vaccines (Basel). 2023 Oct 21;11(10):1621. doi: 10.3390/vaccines11101621. PMID: 37897023.
McCullough PA, Wynn C, Procter BC. Clinical Rationale for SARS-CoV-2 Base Spike Protein Detoxification in Post COVID-19 and Vaccine Injury Syndromes. Journal of American Physicians and Surgeons Volume 28 Number 3 Fall 2023, 90-93.